Raymond Kelleher

Raymond J. Kelleher is Managing Director at Cormorant Asset Management, where he invests in public and private companies across all therapeutic areas. He represents Cormorant as Director on the boards of Bridgebio Oncology Therapeutics (NASDAQ: BBOT), Axonis Therapeutics, BiVACOR, GC Therapeutics, Kamau Therapeutics, Neurona Therapeutics, and Triveni Therapeutics as Director, and as Observer on the boards of Antares Therapeutics and Umoja Biopharma. He was formerly a Board Director at Rapport Therapeutics (NASDQ: RAPP) and Interius Biotherapeutics.

Prior to joining Cormorant, Ray was a faculty member and attending neurologist at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS). His clinical practice focused on memory disorders and dementia. His laboratory's research made important contributions to understanding the molecular and cellular basis of neurological disease. His work has been published in Cell, Nature, Neuron, and elsewhere, and his research received numerous national recognitions, including the Pew Scholars Award in the Biomedical Sciences, the John Merck Scholars Award, and the NIH Independent Scientist Award.

Ray completed BS degrees in Biology and Literature at the Massachusetts Institute of Technology (MIT), an AM in French at Harvard University, and an MD and PhD in Cell Biology at Stanford University through the Medical Scientist Training Program. His PhD research with Nobel Laureate Roger Kornberg at Stanford resulted in discovery of the Mediator complex responsible for transcriptional activation, and his postdoctoral research with Nobel Laureate Susumu Tonegawa at MIT identified a key role for translational control in memory formation. He completed his clinical training at MGH and HMS.